Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Published:2016-09 Issue:9 Volume:17 Page:1248-1260
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ascierto Paolo A,McArthur Grant A,Dréno Brigitte,Atkinson Victoria,Liszkay Gabrielle,Di Giacomo Anna Maria,Mandalà Mario,Demidov Lev,Stroyakovskiy Daniil,Thomas Luc,de la Cruz-Merino Luis,Dutriaux Caroline,Garbe Claus,Yan Yibing,Wongchenko Matthew,Chang Ilsung,Hsu Jessie J,Koralek Daniel O,Rooney Isabelle,Ribas Antoni,Larkin James

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Distinct sets of genetic alterations in melanoma;Curtin;N Engl J Med,2005

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

5. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol,2014

Cited by 854 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

3. Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib;Cancers;2024-08-23

4. Terphenyllin induces CASP3-dependent apoptosis and pyroptosis in A375 cells through upregulation of p53;Cell Communication and Signaling;2024-08-21

5. Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors;Molecules;2024-08-16